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Abstract
Background: Our previous studies showed that ZBTB20, a new BTB/POZ-domain gene, could negatively regulate a
feto-protein and other liver-specific genes, concerning such as bio-transformation, glucose metabolism and the
regulation of the somatotropic hormonal axis. The aim of this study is to determine the potential clinical
implications of ZBTB20 in hepatocellular carcinoma (HCC).
Methods: Quantitative real-time RT-PCR and Western blot analyses were used to detect expression levels of
ZBTB20 in 50 paired HCC tumorous and nontumorous tissues and in 20 normal liver tissues. Moreover, expression
of ZBTB20 was assessed by immunohistochemistry of paired tumor and peritumoral liver tissue from 102 patients
who had undergone hepatectomy for histologically proven HCC. And its relationship with clinicopathological
parameters and prognosis was investigated.
Results: Both messenger RNA and protein expression levels of ZBTB20 were elevated significantly in HCC tissues
compared with the paired non-tumor tissues and normal liver tissues. Overexpressed ZBTB20 protein in HCC was
significantly associated with vein invasion (P = 0.016). Importantly, the recurrence or metastasis rates of HCCs with
higher ZBTB20 expression were markedly greater than those of HCCs with lower expression (P = 0.003, P = 0.00015,
respectively). Univariate and multivariate analyses revealed that ZBTB20 overexpression was an independent
prognostic factor for HCC. The disease-free survival period and over-all survival period in patients with
overexpressed ZBTB20 in HCC was significantly reduced.
Conclusions: The expression of ZBTB20 is increased in HCC and associated with poor prognosis in patients with
HCC, implicating ZBTB20 as a candidate prognostic marker in HCC.
Background
Hepatocellular carcinoma (HCC) is the fifth most-com-
mon malignancy in the world and is the third cause of
cancer-related death worldwide. The development and
progression of HCC is a complicated process involving
multiple genes and several transforming steps [1,2]. The
exact molecular mechanisms underlying hepatocarcino-
genesis have not yet been elucidated. Therefore, search-
ing for new HCC associated molecules may give some
clues to study the mechanism of HCC and provide
prognostic value in clinical issues.
The BTB/POZ-ZF [Broad complex, Tramtrack, Bric a’
brac (BTB) or poxvirus and zinc finger (POZ)-zinc
finger] protein family comprises a diverse group of tran-
scription factors. These factors are so named because of
a distinct and unique N-terminal BTB/POZ domain and
C-terminal DNA-binding zinc finger domains. These
proteins have been demonstrated to participate in a
wide variety of cellular functions including transcrip-
tional regulation, cellular proliferation, apoptosis, cell
morphogenesis, ion channel assembly, and protein
degradation through ubiquitination-proteasome system
[3-5]. A subset of BTB/POZ proteins have been
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cell lymphoma 6) [6-9], PLZF (promyelocytic leukemia
zinc finger) [10-14], leukemia/lymphoma-related factor
(LRF)/Pokemon [15-18], HIC-1 (hypermethylated in
cancer-1) [19-23], NAC-1[24-29] and Kaiso [30-33].
Z B T B 2 0g e n e ,a l s on a m e dD P Z F[ 3 4 ] ,H O F[ 3 5 ] ,a n d
ZNF288 [36], is a new member of the BTB/POZ-ZF
family. It has two isoforms due to the alternative
translation initiation, both containing an intact
N-terminal BTB domain and a C-terminal zinc finger
domain [35]. Zbtb20 is preferentially expressed by hip-
pocampal progenitors, and essential for hippocampal
development [37].
In liver, our previous work showed that human
ZBTB20 is expressed in fetal liver [34]. In mouse, Zbtb20
is developmentally up-regulated in postnatal liver, and
acts as a key transcription repressor of AFP [38]. What’s
more, ZBTB20 may play an essential role in liver intrinsic
functions, possibly through regulating genes such as P450
family members, glucose metabolism and the regulation
of the somatotropic hormonal axis [39].
In the present study, we investigated the expression of
ZBTB20 in HCC tissues and its potential association
with clinicopathological features and post-resectional
survival. Our results suggested that ZBTB20 overexpres-
sion can be used as an independent marker for the
prognosis of patients with HCC.
Methods
Patients and liver specimens
Primary HCC tissue sample (n = 152) were randomly
obtained from patients who underwent routine curative
surgery at the Eastern Hepatobiliary Surgery Hospital
between 2001 and 2007. The patients were not pre-
treated with radiotherapy or chemotherapy prior to sur-
gery. Among them, 102 tissue samples were fixed in
10% formalin and embedded in paraffin for immunohis-
tochemical analysis. The other 50 tissue samples were
immediately frozen in liquid nitrogen and stored at -80°
C after hepatectomy for western blotting and real-time
RT-PCR. Table 1 shows the clinicopathological features
of these patients. Additionally, normal liver specimens
were obtained from 20 patients with hemangiomas of
liver who underwent surgery. The 20 cirrhotic liver spe-
cimens were obtained from patients who underwent
liver biopsy. The diagnoses were confirmed by histo-
pathologic study. Tumor stage was determined accord-
ing to the 2002 International Union Against Cancer
TNM classification system [40]. Tumor differentiation
was graded by the Edmondson grading system. Written
informed consent was obtained from these patients, and
the protocol for this study was approved by the Ethics
Committee of the Eastern Hepatobiliary Surgery
Hospital.
Cells and cell culture
L02, QSG7701, PLC/PRF/5, SMMC7721, HepG2,
S K - H e p - 1 ,W R L 6 8 ,H e p 3 B ,H u h 7 ,H C C C L M 3 ,a n d
HCCC97L cell lines were obtained from American Type
Culture Collection (Manassas, VA) or Cell bank of Chi-
nese Academy of Sciences (Shanghai, China). All cells
were cultured in DMEM (GiBco BRL, Life Technologies)
with 10% fetal bovine serum at 37°C in a humidified 5%
CO2 atmosphere.
Immunohistochemistry
Histological diagnoses of tumourous and non-tumour-
ous formalin-fixed and paraffin-embedded tissues were
Table 1 Clinicopathological parameters of 152 patients
with HCC
Clinicopathological parameters variables n, range All patients
(n = 152)
Age(years)
>50 84
≤50 68
Gender
Male 118
Female 34
Virus
HBV 124
HCV 4
Both 0
None 24
AFP(ng/ml)
≤20 36
>20 116
Liver cirrhosis
Yes 108
No 44
Pathological stage
I3
II 13
III 131
IV 5
Tumour size (mm)
>50 112
≤50 40
Tumour multiplicity
Solitary 121
Multiple 31
Vein invasion
Absent 127
Present 25
Tumor encapsulation
Complete 65
Uncomplete 34
No 53
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Page 2 of 12confirmed on haematoxylin and eosin-stained sections.
T h et i s s u es e c t i o n s( 3 - μm thick) were dewaxed, rehy-
drated and then immersed in methanol containing 0.3%
hydrogen peroxide for 30 min to block endogenous per-
oxidase activity. Subsequently, the sections were heated
in a pressure cooker filled with 10 mM ethylenediamine-
tetracetic acid (EDTA) buffer (pH 8.0) for 2 min. After
cooling, the sections were incubated in 1% blocking
serum for 30 min to reduce nonspecific binding. Pri-
mary anti-ZBTB20 polyclonal antibodies[39] were
diluted 1:350 and incubated with the sections at 4°C
overnight. Following incubation with biotinylated sec-
ondary antisera, the streptavidin-biotin complex/horse-
radish peroxidase was applied. Finally, the visualization
signal was developed with diaminobenzidine (DAB) and
the slides were counterstained in hematoxylin.
Stained sections were evaluated in a blinded manner
without prior knowledge of the clinical information
using the German immunoreactive score, Immuno-
Reactive-Score (IRS). Briefly, the IRS assigns sub-scores
for immunoreactive distribution (0-4) and intensity
(0-3), then multiplies them to yield the IRS score. The
percent positivity was scored as “0” (<5%), “1” (5-25%),
“2” (25-50%), “3” (50-75%,), “4” (>75%). The staining
intensity was score as “0” (no staining), “1” (weakly
stained), “2” (moderately stained), and “3” (strongly
stained). The final ZBTB20 expression score was calcu-
lated with the value of percent positivity score plus
staining intensity score, which ranged from 0 to 12
(Figure 1). We estimated IRS by averaging the values
in eight fields at ×400 magnification for each speci-
men. Intratumoral/peritumoral ZBTB20 expression was
defined as follows: low expression (score 0-6/0-3) and
high expression (score > 6/4-6). Immunohistochemical
analysis and scoring were performed by 2 independent
investigators.
Figure 1 Typical scored immunohistochemical staining of liver tissue specimens. Formalin-fixed and paraffin-embedded tissues were
incubated with primary anti-ZBTB20 polyclonal antibodies (diluted 1:350) at 4°C overnight. The visualization signal was developed with
diaminobenzidine (DAB) and the slides were counterstained in hematoxylin. Total score was calculated from sub-scores of staining distribution
(0-4) and intensity (0-3).
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Page 3 of 12RNA extraction, cDNA synthesis and real-time RT-PCR
Total RNA was extracted from frozen tissue specimens
(50-100 mg) using Trizol reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’sp r o t o c o l .
The RNA was reverse transcribed using RT-PCR kits
(Applied Biosystems, Foster City, CA, USA) with an
oligo d (T) primer under standard conditions. Real-time
ZBTB20 PCR amplification was performed in 1× Uni-
versal Master Mix (Applied Biosystems) with gene-speci-
fic primers and probe on the ABI Prism 7300 Sequence
Detection System, according to the manufacturer’s
instructions. The 18s rRNA levels were quantified as
internal control to normalize the expression of each
gene. Each reaction was repeated independently at least
three times. The following primers were used: ZBTB20,
sense 5’- ATGCTAGAACGGAAGAAACCCA -3’,a n t i -
sense 5’-TGTGAGCGTGAGAGTTTGTCA -3’;18s,
sense 5’-GGGAGGTAGTGACGAAAAA T-3’ and anti-
sense 5’-ACCAACAAAATAGAACCGCG-3’. Relative
expression levels of genes were calculated and expressed
as 2
ΔCt.
Western blotting analysis
Western blotting was performed as previously described
[41]. In brief, the tissues or cells were lysed in RIPA buf-
fer, sonicated, and protein concentrations calculated by
Bicinchoninic acid (BCA) (Sigma). About 60 μgp r o t e i n
samples were run on a 12% SDS-PAGE gel and trans-
ferred to a polyvinylidine difluoride membrane. Mem-
branes were blocked for 1 h in Tris-buffered saline with
0.05% Tween 20 (TBST) containing 5% skim milk. The
membrane was probed with ZBTB20 antibody (dilution,
1:2000) overnight followed by washing triplely with
TBST for 5 min and incubated with an IRDye 800CW-
conjugated secondary antibody. After being washed
three times, the membrane was detected with LI-COR
imaging system (LI-COR Biosciences). Mouse anti-
human b-actin antibody (dilution, 1:1000; Santa Cruz)
was applied as an internal control. The signal intensity
of each band on scanned autoradiograms was analysed
using LI-COR imaging system. We normalised each
sample to the intensity of the b-actin band, and then
estimated the value as an expression index.
Follow-Up
Follow-up data were obtained for all the 102 patients
with immunohistochemical analysis. The follow-up per-
iod was defined as the interval from the date of opera-
tion to the date of death or the last follow-up. Deaths
from other causes were treated as censored cases.
Recurrence and metastasis were diagnosed by clinical
examination, AFP measurement, liver ultrasonography,
and computed tomography (CT) scan. All patients were
observed until December 2009, ranged from 29 to 103
months (median, 73 months). Overall survival (OS) was
defined as the interval between the dates of surgery and
death. Disease-free survival (DFS) was defined as the
interval between the dates of surgery and recurrence; if
recurrence was not diagnosed, patients were censored
on the date of death or the last follow-up.
To determine factors influencing survival after opera-
tion, 13 conventional variables together with ZBTB20
expression were tested in 102 patients: age (≤50 years vs
>50 years), gender, tumor size (≤50 mm vs >50 mm),
serum AFP level (≤20 ng/mL vs >20 ng/mL), HBsAg
(positive vs negative), Edmondson-Steiner grade (I-II vs
III-IV), liver cirrhosis (yes vs no), tumor encapsulation
(complete vs uncomplete vs no), vein invasion (yes vs
no), tumour multiplicity (solitary vs multiple), TNM
stage (I-II vs III), recurrence (yes vs no), metastasis (yes
vs no), and ZBTB20 intratumoral/peritumoral protein
expression level (high vs low).
Statistical analysis
A paired-samples t-test was used to compare the mRNA
and protein expression of ZBTB20 between HCC
tumorous and the pair-matched non-tumor tissues sam-
ples. The Pearsontest or Fisher’se x a c tt e s tw a su s e dt o
analyze the relationship between ZBTB20 expression
and the clinicopathologic features. The correlation
between the expression of ZBTB20 and AFP was
explored using Spearman’s correlation analysis. Survival
curves were calculated using the Kaplan-Meier method
and compared by the log-rank test. The Cox propor-
tional-hazard regression model was used for univariate
and multivariate analyses to explore the effect of the
clinicopathological variables and ZBTB20 expression on
survival. SPSS 16.0 software (SPSS Inc., Chicago, IL,
USA) was used for all statistical analyses and a p value
< 0.05 was considered significant.
Results
Increased Expression Levels of ZBTB20 Messenger RNA
and Protein in Hepatocellular Carcinoma
Our previous work showed that ZBTB20 was develop-
mentally up-regulated in liver and was a key repressor
governing AFP gene transcription in postpartum liver,
and may play an essential role in liver intrinsic functions
by regulating genes such as P450 family members, glu-
cose metabolism and the regulation of the somatotropic
hormonal axis. To investigate the expression of ZBTB20
and its possible role in HCC, we first detected the pro-
tein expression in three human normal liver cell line
(L02, QSG7701, WRL68) and 8 HCC cell lines (PLC/
PRF/5, SMMC7721, HepG2, SK-Hep-1, Hep3B, Huh7,
HCCCLM3, and HCCC97L). ZBTB20 was high
expressed in most of the cells (Figure 2A, the whole
image was shown in additional file 1). We further
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Page 4 of 12performed real-time RT-PCR for the transcriptional
level of ZBTB20 from 50 frozen paired samples derived
from patients who had undergone hepatectomy for his-
tologically proven HCC. The mRNA level of ZBTB20
was significantly higher in 38 (76%) HCC tissues
(tumour; T) compared with the pair-matched non-
tumor tissues (NT). We calculated the copy number
ratio of ZBTB20 mRNA/18s mRNA. This ratio was sig-
nificantly higher in tumor samples than in NT samples
(4.47 ± 2.71 versus 2.32 ± 0.64, P = 0.006) (Figure 2B).
Next, the protein level of ZBTB20 in T and NT speci-
mens of 50 HCC cases was analyzed by western blot
analysis. ZBTB20 signal was found to be positive in all
T samples, and in 78% of NT samples. The intensity of
each protein band was normalised against the expres-
sion of b-actin in each sample, and this ratio was treated
as an expression index. Consistent with mRNA expres-
sion, the protein level of ZBTB20 in HCC tumor tissues
was also significantly higher than that in NT samples
(1.81-fold on average, P < 0.001) (Figure 2C).
Immunohistochemistry Analysis of ZBTB20 Expression
and its Relationship with the Clinicopathological
Parameters
To investigate the effect and the prognostic value of
ZBTB20, immunohistochemistry was used to assess the
expression of ZBTB20 in the HCC tissues sections. It
was showed that ZBTB20 staining was mainly in the
nucleus of tumor cells, partly in the cytoplasm.
ZBTB20 expression in normal hepatocytes from para-
tumoral tissue of hemangiomas of liver and cirrhotic
l i v e rw e r en e g a t i v eo rw e a k l yp o s i t i v e( F i g u r e3 A , B ) ,
while mainly moderate or strong positive in HCC
tumors (Figure 3C). Overall, 42 of the 102 (41.2%)
cases showed high expression (IRS over 6) ZBTB20 in
the tumorous tissues, while 60 (58.8%) of the cases
showed low expression (IRS 0-6). Generally, ZBTB20
density was significantly higher in intratumoral tissues
than in peritumoral tissues (6.37 ± 3.17 versus 2.73 ±
1.68, P < 0.001) (Table 2). Additionally, a sharp con-
trast was often observed between infiltrative tumorous
areas of positive staining and the adjacent nontumor-
ous area of negative staining (Figure 3D).
We analysed the relationship between ZBTB20 protein
expression and clinical features of HCC by establishing
two groups with high and low ZBTB20 expression
respectively based on the results of immunohistochemis-
try analysis. As shown in Table 3, intratumoral ZBTB20
density were positively correlated with vein invasion,
recurrence and metastasis. Meanwhile, patients with
high peritumoral ZBTB20 density were prone to recur-
rence. There was no significant association between
ZBTB20 expression and the other clinical features, such
as age, gender, tumor size, serum AFP level, HBsAg,
Edmondson-Steiner grade, liver cirrhosis, tumor encap-
sulation, tumour multiplicity or TNM stage.
O u rp a s tw o r ks h o w e dt h a tZ B T B 2 0n e g a t i v e l yr e g u -
lated AFP [38]. However, in this work, no correlation
between serum AFP level and tissue ZBTB20 protein
expression was found. Considering the possible discre-
pancy of serum and liver tissue AFP level, we examined
possible relationship between tissue AFP staining level
and ZBTB20 expression level in HCCs, adopting Spear-
man’s correlation analysis. In 102 samples, 61.8% cases
Figure 2 ZBTB20 expression in HCC tissues and HCC cell lines. A. Western blot analysis of ZBTB20 in HCC cell and normal liver cell lines. B.
Evaluation of ZBTB20 mRNA in HCC. C. Western blot analysis of ZBTB20 in HCC and normal liver tissues. T Tumor tissue; NT non-tumor tissue; NL
normal liver. D. Expression index of ZBTB20 protein. ZBTB20 protein expression level in HCC was significantly higher than those in NT (P < 0.001).
The data are representative of three independent experiments.**: T compared with NT or NL, p <0.05.
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AFP; 29.4% cases (30/102) showed low IRS of ZBTB20
with high IRS of AFP; and 8.8% cases (9/102) showed
almost the same level of IRS. As shown in Figure 4, the
ZBTB20 level was negatively correlated with the staining
degree of AFP in HCCs (r = -0.33, P = 0.001), while the
serum AFP level had no significant correlation with the
tissue AFP IRS (P= 0.538).
Correlation between ZBTB20 Expression and Prognosis
At the time of the last follow-up, 74 patients had tumor
recurrence, and 59 patients had died. The 1-, 3-, and 5-
year OS rates were 77.5%, 53.5%, and 45.9%,
respectively; and the 1-, 3-, and 5-year DFS rates were
52.8%, 33.4%, and 26.5%, respectively. The median OS
and DFS time were 18 months (95%CI, 1.06 months to
34.94 months) and 6 months (95%CI, 3.98 months to
8.01 months), respectively, for patients with high intra-
tumoral ZBTB20 density (IRS over 6, as described in
Materials and methods) and were statistically shorter
than the median OS and DFS time for patients with low
peritumoral ZBTB20 density [67 months (95%CI, 52.53
months to 81.47 months) and 31 months (95%CI, 13.89
months to 48.12 months), respectively (P =0 . 0 0 1a n d
P<0.001, respectively; Figure 5A and 5B)]. Besides,
patients with high peritumoral ZBTB20 had poor DFS
(9 months vs 22 months, P = 0.002; Figure 5D), whereas
peritumoral ZBTB20 was not associated with OS (P =
0.225; Figure 5C)
Univariate Cox regression analyses determined that
tumor size, serum AFP, TNM stage, tumor number,
tumor encapsulation, vein invasion and intratumoral
ZBTB20 expression were significantly associated with
OS; while tumor size, HBsAg positive, TNM stage, tumor
number, vein invasion and intratumoral/peritumoral
ZBTB20 expression were associated with DFS. Further-
more, multivariate Cox regression analyses revealed that
high intratumoral ZBTB20 was independent risk factor
Figure 3 Immunohistochemistry detection of ZBTB20 expression in normal liver tissue, cirrhotic liver tissue, HCC (T) and in
noncancerous hepatic tissues (N). A. Normal liver tissue. B. Cirrhotic liver tissue. The expression of ZBTB20 was weakly positive in hepatocytes.
C. HCC cells stained strongly positive with a large granular pattern. D The boundary area between the tumor and non-tumor lesion. Hepatocytes
adjacent to HCC lesion were stained with a small granular pattern. Original magnification, ×200. T, tumor; N, Paired-nontumor tissue.
Table 2 Average Density of Normal liver, Cirrhotic liver,
Peritumoral and Intratumoral ZBTB20
staining density p
mean Standard deviation range
Normal liver 1 0.93 0-3 <0.001*
Cirrhotic liver 2.46 0.91 0-4 <0.001**
Peritumoral 2.73 1.68 0-6 <0.001***
Intratumoral 6.17 3.17 0-12 <0.001****
Abbreviations: * Normal liver tissue vs Cirrhostic liver tissue; ** Normal liver
tissue vs Peritumoral; *** Normal liver tissue vs Intratumoral; ****Peritumoral vs
Intratumoral.
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Page 6 of 12for OS (relative risk [RR] = 1.952, P = 0.016) and DFS
(RR = 2.094, P = 0.003) (Table 4). Besides, tumor size
large than 50 mm and vein invasion were also indepen-
dent predictors for the OS of HCC patients (P =0 . 0 0 6
and 0.086, respectively; Table 4), while the others failed
to show this independence.
Using 12 months as the cutoff value, all of the recur-
rences were divided into early recurrence, which is
mainly from intrahepatic metastasis, and late recurrence,
which is usually a result of a multicentric new tumor
[42]. Patients with higher intratumoral ZBTB20 density
w e r ep r o n et oh a v ea ne a r l yrecurrence compared with
Table 3 Relationship Between Intratumoral and Peritumoral ZBTB20 and Clinicopathologic Features
Intratumoral ZBTB20 Peritumoral ZBTB20
Variable High
(n = 42, 41.2%)
Low
(n = 60, 58.8%)
P High
(n = 42, 41.2%)
Low
(n = 60, 58.8%)
P
Age(years) 0.523 1.0
≤50 19 31 20 30
>50 23 29 22 30
Gender 0.188 0.188
Male 36 45 36 45
Female 6 15 6 15
Tumor size(mm) 0.299 0.550
≤50 10 20 11 19
>50 32 40 31 41
AFP(ng/ml)
≤20 10 16 0.745 11 15 0.892
>20 32 44 31 45
HBsAg 0.302 0.106
Positive 38 50 39 49
Negtive 4 10 3 11
Pathological stage 0.396* 1.0*
I-II 1 5 2 4
III-IV 41 55 40 56
Liver cirrhosis 0.675 0.172
Yes 31 42 27 46
No 11 18 15 14
Tumor encapsulation 0.235 0.446
Complete 12 27 13 26
Uncomplete 10 10 9 11
No 20 23 20 23
Vein invasion 0.016 0.161
Present 13 7 11 9
Absent 29 53 31 51
Tumour multiplicity 0.064 0.589
Solitary 25 46 28 43
Multiple 17 14 14 17
TNM stage 0.07 0.573
I-II 22 5 25 39
III 20 55 17 21
Recurrence 0.003 0.001
Yes 37 37 38 36
No 5 23 4 24
Metastasis 0.000 0.08
Yes 27 16 22 21
No 15 44 20 39
Abbreviations: HBsAg, hepatitis B s antigen.
*Twenty-five percent of all the cells have expected count less than 5; Fisher’s exact test.
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Page 7 of 12Figure 4 Expression of ZBTB20 in HCC and correlation with AFP expression. A. The consecutive slices of two samples immunostained by
anti-ZBTB20 or anti-AFP antibody. a&b. Positive staining of AFP in HCC, while negative staining of ZBTB20; c&d. Positive staining of ZBTB20 in
HCC, while negative staining of AFP. Magnification: ×100 & ×200. B. Scatter plot of the correlation of IRS of ZBTB20 with AFP. By Spearman’s
correlation analysis, IRS of ZBTB20 was negatively correlated to AFP (r = - 0.33, P = 0.001).
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Page 8 of 12Figure 5 Cumulative overall and disease-free survival curves of patients with high or low intratumoral or peritumoral features. (A and
B) Low intratumoral ZBTB20 was associated with prolonged overall and disease-free survival (P = 0.001 and P<0.001, respectively). (C and D) Low
peritumoral ZBTB20 was associated with disease-free survival (P = 0.002) but not with overall survival(P = 0.225).
Table 4 Univariate and Multivariate Analyses of Factors Associated With Survival and Recurrence
Factor OS DFS
Multivariate Multivariate
Univariate
P
Hazard
Ratio
95% CI P Univariate
P
Hazard
Ratio
95% CI P
Age: ≤ 50 v >50 years 0.603 NA 0.782 NA
Sex: female v male 0.197 NA 0.254 NA
Liver cirrhosis:n ov yes 0.932 NA 0.194 NA
Tumor size: ≤ 50 v >50 mm 0.001 2.727 1.326-
5.605
0.006 0.001 2.175 1.22-3.875 0.008
AFP: ≤ 20 v >20 ng/ml 0.051 NA 0.070 NS
HBsAg: positive v negative 0.141 NA 0.042 NS
TNM stage: I-II v III 0.002 NS υ0.0001 1.982 1.288-
3.366
0.005
Tumor number: single v multiple 0.017 NS 0.0001 NS
Tumor encapsulation: complete v uncomplete v
no
0.051 NA 0.065 NA
Vein invasion: yes v no 0.001 1.713 0.927-
3.167
0.086 υ0.0001 NS
Intratumoral ZBTB20: low v high 0.001 1.952 1.134-
3.359
0.016 0.0000 2.094 1.296-
3.383
0.003
Peritumoral ZBTB20: low v high 0.225 NA 0.002 NS
Abbreviations: OS, overall survival; DFS, disease-free survival; NA, not adopted; HBsAg, hepatitis B s antigen; NS, not significant.
Wang et al. BMC Cancer 2011, 11:271
http://www.biomedcentral.com/1471-2407/11/271
Page 9 of 12patients with low intratumoral ZBTB20 (7.72 ± 2.9 vs
5.01 ± 2.86, P<0.001) (Table 5).
Discussion
In this study, we examined ZBTB20 expression profiles
and its correlations with clinicopathologic parameters
and prognosis in HCC. Our data revealed that both
mRNA and protein levels of ZBTB20 were significantly
higher in HCC tissues than in the corresponding non-
tumor tissues and normal liver tissues.
We observed that increased expression of ZBTB20 in
HCC was positively correlated with tumor vein invasion,
recurrence and metastasis. Moreover, patients with high
intratumoral ZBTB20 expression had significantly worse
OS and DFS when compared with patients with low
expression of ZBTB20. Multivariate analysis demon-
strated that among the factors analyzed, intratumoral
ZBTB20 expression was an independent prognostic fac-
tor for OS and DFS in patients with HCC. Meanwhile,
tumor size, serum AFP, TNM stage, tumor number and
vein invasion were all independent prognostic factors
for OS; while tumor size, HBsAg positive, TNM stage,
tumor number, vein invasion and peritumoral ZBTB20
expression were independent prognostic factors for DFS.
These results clearly demonstrated that high ZBTB20
expression is associated with poor progression and unfa-
vorable clinical outcome of HCC. This showed that high
ZBTB20 expression in HCC is an indicator of poor
prognosis.
Our earlier work demonstrated that ZBTB20 was a
key repressor governing AFP gene transcription in post-
partum liver. In this report, our data didn’ts h o wa n y
relationship between ZBTB20 expression and serum
AFP value. However, ZBTB20 and AFP expression, both
of tumor tissue origin, were really inversely related
(Figure 4). This was in keeping with the inconsistant
relation between serum and tissue AFP level in HCC
cases (unpublished data).
The close relationship between ZBTB20 expression
and clinicopathological features predicted that ZBTB20
might boost carcinogenesis and tumor progression. Cur-
rently, several BTB/POZ-ZF proteins have been impli-
cated in various cancers. For example, the BCL6 and
PLZF proteins are causally involved in several types of
B-cell lymphomas and acute promyelocytic leukaemia
[6-11]. NAC-1 is significantly overexpressed in ovarian
serous carcinomas and intense NAC-1 immunoreactivity
in primary tumors predicts early recurrence [26]
whereas transgenic mice that overexpress Pokemon
develop aggressive tumours [15]. Among these proteins,
their BTB/POZ domains play a critical role in carcino-
genesis and tumor progression. Some researches sug-
gested that targeting the BTB/POZ domain of BCL-6
caused apoptosis and cell cycle arrest, providing a novel
approach for cancer therapy [7]. More recently, Cerch-
ietti LC et al found that shock protein 90 (Hsp90) inhi-
bitors selectively kill a subset of Diffuse Large B-cell
Lymphomas (DLBCL) that are biologically dependent on
the Bcl6 transcriptional repressor, through interrupting
direct interaction between BCL-6 and Hsp90 followed
by accelerated BCL-6 degradation [43].
Conclusion
We demonstrated here, that ZBTB20 is overexpressed in
a large proportion of patients with HCC and high
ZBTB20 expression correlated with the disease progres-
sion and poor clinical outcome in HCC. Furthermore,
ZBTB20 proved to be a risk factor for tumor recurrence
and independent molecular marker of prognosis in HCC
and may become a novel molecular target in the strate-
gies for the prediction of tumor recurrence and prog-
nosis or treatment of HCC.
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negative control. Molecular Marker. N: Non-tumor T: Tumor. L:293T cell
line transiently transfected with ZBTB20-expressing plasmid; R: 293T cell
line transiently transfected with empty plasmid. Arrowhead indicates the
ZBTB20 ladder.
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